Toggle navigation
About
Abstract
Editorial Board
Subscription & Newsletter
Contact
Issues
This issue
18-1
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
18-1
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Abstracts
Index of Authors
Author #85116
advertisement
Ukegawa K
15
Showing records 1 to 15 |
Display all abstracts from
Ukegawa K
69028
Relationship between oxygen saturation of the retinal vessels and visual field defect in glaucoma patients: comparison with each hemifield
Shimazaki T
Acta Ophthalmologica
2016; 94: e683-e687
69364
Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Sato S
Advances in Therapy
2016; 33: 1628-1634
69420
Estimating the rate of retinal ganglion cell loss to detect glaucoma progression: An observational cohort study
Hirooka K
Medicine
2016; 95: e4209
69364
Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Hirooka K
Advances in Therapy
2016; 33: 1628-1634
69420
Estimating the rate of retinal ganglion cell loss to detect glaucoma progression: An observational cohort study
Izumibata S
Medicine
2016; 95: e4209
69028
Relationship between oxygen saturation of the retinal vessels and visual field defect in glaucoma patients: comparison with each hemifield
Hirooka K
Acta Ophthalmologica
2016; 94: e683-e687
69420
Estimating the rate of retinal ganglion cell loss to detect glaucoma progression: An observational cohort study
Ukegawa K
Medicine
2016; 95: e4209
69364
Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Nitta E
Advances in Therapy
2016; 33: 1628-1634
69028
Relationship between oxygen saturation of the retinal vessels and visual field defect in glaucoma patients: comparison with each hemifield
Nakano Y
Acta Ophthalmologica
2016; 94: e683-e687
69364
Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Ukegawa K
Advances in Therapy
2016; 33: 1628-1634
69420
Estimating the rate of retinal ganglion cell loss to detect glaucoma progression: An observational cohort study
Nitta E
Medicine
2016; 95: e4209
69028
Relationship between oxygen saturation of the retinal vessels and visual field defect in glaucoma patients: comparison with each hemifield
Nitta E; Ukegawa K
Acta Ophthalmologica
2016; 94: e683-e687
69364
Additive Intraocular Pressure Lowering Effects of the Rho Kinase Inhibitor, Ripasudil in Glaucoma Patients Not Able to Obtain Adequate Control After Other Maximal Tolerated Medical Therapy
Tsujikawa A
Advances in Therapy
2016; 33: 1628-1634
69420
Estimating the rate of retinal ganglion cell loss to detect glaucoma progression: An observational cohort study
Tsujikawa A
Medicine
2016; 95: e4209
69028
Relationship between oxygen saturation of the retinal vessels and visual field defect in glaucoma patients: comparison with each hemifield
Sato S; Tsujikawa A
Acta Ophthalmologica
2016; 94: e683-e687
Issue
18-1
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept